Alternative and terminal complement pathways. Complement factor H (CFH), along with its related proteins (CFHRs), inhibits amplification of C3b. Eculizumab binds C5, preventing conversion to C5b and subsequent formation of the membrane attack complex (MAC), which effects cell lysis and mediates renal epithelial damage.